Axalimogene filolisbac

Drug Overview

Axalimogene filolisbac is an innovative form of Immunotherapy and a “Smart Drug” designed to fight cancers caused by the Human Papillomavirus (HPV). Unlike traditional treatments that attack all fast-growing cells, this therapy uses a modified bacterium to “teach” the immune system how to find and destroy specific cancer cells.

• Generic Name: Axalimogene filolisbac (also known as ADXS11-001).
• US Brand Names: None (Currently an Investigational Drug).
• Drug Class: Antigen-specific Cancer Immunotherapy; Live-attenuated Bacterial Vector Vaccine.
• Route of Administration: Intravenous (IV) Infusion.
• FDA Approval Status: Investigational. It has received “Fast Track” and “Orphan Drug” designations for certain HPV-associated cancers, but is currently in Phase 2 and Phase 3 clinical trials.

What Is It and How Does It Work? (Mechanism of Action)

Axalimogene filolisbac works as a Targeted Therapy by using a weakened version of the bacterium Listeria monocytogenes. This bacterium has been genetically engineered to be safe for humans while acting as a delivery vehicle for a cancer-fighting message.

Molecular Delivery (The Listeria Vector)

The therapy uses the Listeria bacterium because it has a unique ability to enter Antigen-Presenting Cells (APCs), which are the “scouts” of the immune system. Once inside these cells, the bacterium releases a fusion protein called tLLO-E7.

Targeting the HPV “Fingerprint” (E7 Antigen)

• The Message: The “E7” part of the protein is a specific marker found on HPV-infected cancer cells.
• The Training: Inside the scout cells, the protein is broken down and displayed on the cell surface using MHC Class I and II pathways.
• The Activation: This process signals the immune system to create a massive army of Killer T-cells (CD8+) specifically programmed to recognize the E7 protein.

Breaking the Cancer’s Defense

At the molecular level, this therapy also works to weaken the “shield” that tumors use to hide. It reduces the activity of Regulatory T-cells (Tregs) and Myeloid-Derived Suppressor Cells (MDSCs) within the tumor. By removing these “brakes,” the newly trained Killer T-cells can easily enter the tumor and destroy the cancer cells.

FDA Approved Clinical Indications

As an investigational agent, axalimogene filolisbac does not yet have a standard FDA approval for general prescription. However, it is being studied for the following oncological uses:

• Oncological Uses:
  • Persistent, recurrent, or metastatic Cervical Cancer.
  • HPV-associated Oropharyngeal Cancer (Head and Neck Cancer).
  • HPV-associated Anal Cancer.
• Non-oncological Uses:
  • None.

Dosage and Administration Protocols

Because this is a live-attenuated bacterial therapy, it is administered in a controlled clinical environment with specific “pre-medication” to ensure patient safety.

Dose Adjustments:

• Renal/Hepatic Insufficiency: There are no standard dose adjustments for kidney or liver issues yet, but patients must have stable organ function to safely process the follow-up antibiotics.
• Fever Management: If a high fever occurs during infusion, the rate may be slowed or stopped.

Clinical Efficacy and Research Results

Current research (2020–2025) has focused on how this vaccine performs in patients who have not responded to standard chemotherapy.

• Cervical Cancer (GOG-0265 Study): In a Phase 2 study of patients with persistent or recurrent cervical cancer, axalimogene filolisbac showed a 12-month Overall Survival (OS) rate of approximately 38%. This was a significant improvement over the historical expected survival rate for this group.
• Survival Benefit: Data indicates that even patients who do not see a “shrinkage” of the tumor on scans may still experience an “overall survival benefit,” as the immune system keeps the cancer from growing.
• Combination Efficacy: Recent trials are testing this drug alongside “checkpoint inhibitors” (like Durvalumab). Early results suggest that combining these two types of immunotherapy may double the response rate compared to using either drug alone.

Safety Profile and Side Effects

The side effects of this therapy are unique because they are related to the body’s natural response to the Listeria bacterium.

Black Box Warning: There is currently no official Black Box Warning, but investigators monitor closely for Listeriosis-related sepsis and severe infusion-related reactions.

Common Side Effects (>10%)

• Chills and Rigors: Shaking during or shortly after the infusion (very common).
• Fever: Often occurring within hours of treatment.
• Nausea and Vomiting.
• Fatigue: General tiredness.
• Headache.

Serious Adverse Events

• Severe Infusion Reactions: Low blood pressure or difficulty breathing during the drip.
• Sepsis: A dangerous blood infection if the follow-up antibiotics are not taken correctly.
• Hypotension: Significant drop in blood pressure.

Management Strategies

• Infusion Care: Slowing the infusion rate usually manages shaking and chills.
• Antibiotic Coverage: It is mandatory to complete the prescribed antibiotic course after treatment to kill the bacterial delivery vehicle.
• Fever Control: Over-the-counter fever reducers are used to manage post-treatment temperatures.

Research Areas

Axalimogene filolisbac is at the forefront of Immunotherapy research. While it is not a “stem cell” therapy, it is being studied as a way to “reprogram” the immune environment of a tumor. Researchers are investigating if this therapy can be used before surgery (neoadjuvant) to prime the immune system, potentially reducing the chance of cancer recurrence. It is also being explored in combination with Adoptive Cell Transfer, where T-cells are harvested, trained by the vaccine, and then re-infused into the patient.

Patient Management and Practical Recommendations

Pre-treatment Tests

• HPV Status: Testing to confirm the tumor is HPV-positive.
• Immune Baseline: Blood tests to ensure the patient is not severely immunocompromised.
• Infection Screening: Ensuring the patient does not have an active uncontrolled infection.

Precautions During Treatment

• Antibiotic Compliance: You must take your antibiotics exactly as scheduled after the infusion.
• Fever Monitoring: Expect a fever after treatment, but report a fever that lasts longer than 24 hours.

“Do’s and Don’ts” List

• DO tell your doctor about any allergies to antibiotics (especially Penicillin).
• DO stay hydrated before and after your infusion.
• DON’T miss your follow-up antibiotic dose; this is a safety requirement.
• DON’T worry about “chills” during the infusion; this is a sign the medicine is starting to work.

Legal Disclaimer

This guide is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Axalimogene filolisbac is an investigational drug and is only available through clinical trials. Always consult with a qualified oncologist to discuss your specific medical condition and potential treatment options. Individual results from clinical trials may vary.